The 2025 @Philly Cell and Gene Therapy (CGT) Conference, hosted by SAPA-GP (Sino-American Pharmaceutical Professionals Association -Greater Philadelphia)) on June 27–28 at the Sheraton Valley Forge Hotel, brought together over 450 professionals from across the biopharma ecosystem. From scientific pioneers and startup founders to policy advocates and patient voices, the event showcased the full spectrum of innovation and collaboration driving the future of cell and gene therapy.
Now in its fourth year, the 2025 @Philly CGT Conference has quickly become one of the largest biotech gatherings in the Philadelphia region. Organized by SAPA-GP—a nonprofit founded in 2002 to support life science professionals in the Greater Philadelphia—the conference featured a dynamic mix of keynote talks, scientific sessions, business panels, and networking opportunities.
A Call to Action from a Pioneer
The conference opened with a powerful keynote from Dr. James Wilson, CEO of GEMMA Biotherapeutics and a pioneer in gene therapy. Drawing from decades of experience, Wilson reflected on the evolving landscape of rare disease investment and the critical role of patient advocacy in shaping the future of the field.
He noted that while the current funding climate presents challenges, it also forces startups to be more intentional—tracking every dollar and making smarter, more strategic decisions. In his view, this kind of financial discipline could ultimately lead to stronger, more resilient companies.
Wilson also spoke to the need for unity in the industry, especially among early-stage companies. “We can’t afford to knock each other down,” he said, urging the community to prioritize collaboration over competition.
Business Meets Science
The conference featured 10 business panels across four tracks, covering everything from early-stage funding and commercialization to AI, policy, and global strategy. I had the honor of participating in the Keystone LifeSci Collaborative panel on expanding Philly’s talent pipeline, where we discussed how to better connect academic training with industry needs.
Other standout sessions included:
- “Money in the Bank” – on structuring early funding to attract future capital
- “Women in Business: The Philly Story” – highlighting female leadership in biotech
- “Sound Policy” – a timely discussion on how local and state governments can support life sciences growth
Scientific Innovation on Display
On the scientific side, sessions covered the latest in CMC, gene therapy, cell therapy, RNA therapeutics, and regulatory / clinical development. Talks ranged from innovations in plasmid development and AAV manufacturing to CRISPR safety and next-gen delivery platforms.
The company showcase featured emerging players like Qiagen, Hopstem Biotechnology, and Countable Labs, each presenting novel approaches to some of the field’s most pressing challenges.
A Human Moment
One of the most moving parts of the conference came during the Friday evening Fireside Chat, where Kevin Huang, CEO of the Hope for Rare Foundation, spoke about international collaboration in rare disease research. Hearing directly from a patient advocate was a powerful reminder of why we do this work.
It’s easy to get caught up in the science, the funding rounds, and the policy debates—but hearing a patient story puts everything into perspective. It humanizes the industry and re-centers the mission: to bring hope and healing to those who need it most.
Looking Ahead
As a BioBuzz Ambassador and someone deeply engaged in the Philly life sciences community, I left the conference feeling energized. Despite the economic, regulatory, and scientific challenges facing the industry, the spirit of collaboration was unmistakable.
The message from the conference was clear: We’re stronger together. Whether within our own state or across neighboring ones, collaboration is the key to advancing cell and gene therapy. From startups and scientists to policymakers and patient advocates, the future of this industry depends on our ability to work together, share resources, and stay focused on the people we’re ultimately here to serve.
